Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.75 |
| ▸ | HTR2C | P28335 | 9/20 | 0.75 |
| ▸ | HTR2B | P41595 | 9/20 | 0.75 |
| ▸ | PNMT | P11086 | 8/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | CD44 | P16070 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6187756 | 1.00 | HTR2A (0.75) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL11359434 | 0.98 | PNMT (0.73) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL7885461 | 0.86 | HTR2A (1.00) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL1772370 | 0.84 | PNMT (1.00) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL11211829 | 0.82 | PNMT (1.00) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL6222916 | 0.81 | PNMT (0.68) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL22993478 | 0.81 | HTR2A (0.50) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL31173285 | 0.81 | HTR2C (0.77) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL30260143 | 0.81 | HTR2C (0.77) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL23022301 | 0.81 | PNMT (0.53) | HTR2AHTR2CHTR2BPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | HTR2A 1122/4885HTR2C 1719/4885HTR2B 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.